Computational Drug Discovery, which uses computational techniques to facilitate and improve the drug discovery process, has aroused considerable interests in recent years. Drug Repositioning (DR) and DrugDrug Interaction (DDI) prediction are two key problems in drug discovery and many computational techniques have been proposed for them in the last decade. Although these two problems have mostly been researched separately in the past, both DR and DDI can be formulated as the problem of detecting positive interactions between data entities (DR is between drug and disease, and DDI is between pairwise drugs). The challenge in both problems is that we can only observe a very small portion of positive interactions. In this paper, we propose a novel framework called Dyadic PositiveUnlabeled learning (DyPU) to solve the problem of detecting positive interactions. DyPU forces positive data pairs to rank higher than the average score of unlabeled data pairs. Moreover, we also derive the dual formulation of the proposed method with the rectifier scoring function and we show that the associated non-trivial proximal operator admits a closed form solution. Extensive experiments are conducted on real drug data sets and the results show that our method achieves superior performance comparing with the state-of-the-art.
Introduction
Drug discovery is a time-consuming and laborious process. By conservative estimates, it now takes at least 10 to 15 years and $500 million to $2 billion to bring a single drug to market [2] . Furthermore, there is a widening productivity gap: research and development spending continues to increase, yet the number of new therapeutic chemical and biological entities approved by the US FDA has been declining since the late 1990s. The lack of e cacy (i.e., whether the drug works better than alternatives) and safety issues (i.e., whether the drug brings serious adverse event and/or drug-drug interactions) are the two major reasons for which a drug fails clinical trials, each accounting for around 30% of failures [12] . Thus the development of computational techniques to predict drug e↵ects and drug-drug interactions holds great promise for reducing the attrition rate and improving the drug discovery process. Drug repositioning is the process of finding additional indications (i.e., diseases) for existing drugs. It presents a promising avenue for identifying better and safer treatments without the full cost or time required for de novo drug development. Many algorithms have been proposed as the hypothesis generation tools for the drug repositioning process because of the huge number of drug-disease pairs [11, 31, 35] . At the same time, as the number of approved drugs is continuously increasing, Drug-Drug Interaction (DDI) has become a serious health and safety issue which draws great attention from both academia and industry. Numerous methods have also been developed for predicting potential DDIs in the last decade [14, 30, 21] .
Both drug repositioning and DDI prediction can be regarded as a binary dyadic prediction problem, which aims to predict the "label" of a data pair. For the drug repositioning problem, a data pair would be composed of a drug and a disease, and its label is +1 if the drug can treat the disease, and 0 otherwise. For DDI prediction, a data pair includes two di↵erent drugs, and its label is +1 if there is an interaction between the two drugs, and 0 otherwise. In both problems, the most general setting is that we have a small set of positive (i.e., +1 labeled) data pairs, while the labels of the remaining data pairs are unknown. Most of the existing computation based methodologies treat those unknown data pairs' labels as 0 [22, 10] . However, this may not be the case in the real world. For example, an unknown drug-disease pair does not mean the drug cannot be used to treat the disease.
It is just not validated or tested, because there is a huge number of distinct drug-disease pairs. We have the same problem for DDI prediction, where in most cases only positive DDIs can be detected.
To address these challenges we propose a general learning framework called Dyadic Positive-Unlabeled (DyPU) learning in this paper. The basic setting for DyPU is as follows: we are given a set of data pairs and there is a binary label associated with each pair, some of which are known as positive (+1) with the rest unknown; how can we make use of this small portion of positive data pairs together with the rest unlabeled data pairs to identify positive pairs from the unlabeled data pairs. Inspired by the "ranking at the top" problem [18, 3, 5] , we introduce a scoring function that assigns ranking scores to each data pair. The ranking scores of positive pairs are required to be higher than those of negative pairs. Di↵erent from the classic binary classification or bipartite ranking problem where binary labels or pairwise relations are known, we develop a novel model that enables detecting positive data interactions in positive-only and unlabeled settings by forcing positive pairs rank to "on top of" (i.e., having a higher score than) the average score of the unlabeled pairs. Moreover, our model can make full use of information from the two data points in a data pair that may come from two totally di↵erent feature domains. Our proposed framework is able to incorporate di↵erent scoring functions, e.g., the linear function, the sigmoidal function and the rectifier function. When the rectifier function is chosen as the ranking function, the primal optimization problem is hard to solve. We derive the dual formulation of each convex subproblem and show that the associated non-trivial proximal operator of the dual problem admits a closed form solution. We conduct extensive comparison experiments to demonstrate the superiority of the proposed DyPU framework on both drug repositioning and DDI prediction tasks on real world data sets.
It is worthwhile to highlight contributions of this paper.
• We propose a unified computational framework, DyPU, to perform drug repositioning and DDI prediction. Di↵erent from traditional methods using positive and negative pairwise interactions, DyPU works with positive and unlabeled pairwise interactions.
• We propose a novel mechanism to rank each data pair, where positive interaction pairs are ranked on top of the unlabeled interaction pairs.
• We develop a concrete instantiation of DyPU with rectifier scoring function and an e cient proximal algorithm by deriving the analytical form solution of the non-trivial proximal operator associated with its dual problem.
• We validate the DyPU approach on several real world drug data sets and show its advantage over the state-of-the-art algorithms.
Related Work
We will review the related work in this section.
PU Learning
Positive-Unlabeled (PU) Learning [20, 19, 8] refers to a set of learning problems based on positive data points and unlabeled data points. Since there are an unknown portion of positive data points unobserved, directly modelling PU learning problem as a binary classification will lead to highly biased models, which is undesirable. Traditional PU learning approaches can be divided into two categories: the twostep approach and the direct approach [19] . The general idea of the two-step approach is to first identify a set of "reliable negatives" from unlabeled data points and then build binary classifiers on positives and those identified "reliable negatives". The direct approach mainly refers to a weighted classifier where larger weights are imposed on positive errors and smaller weights are imposed on unlabeled errors. The weights are tuning parameters which may be impractical in real-world applications since the distribution of unlabeled positives is unknown. Traditional PU learning approaches are not suitable for incorporating information from multiple domains and thus are not applicable for detecting interactions of data points. Sellamanickam et al. [26] applied pairwise ranking SVM (RSVM) [16, 7] for PU learning where the ranking scores of positives are required to be larger than those of unlabeled scores. For two-class scenario, pairwise ranking SVM is closely related to "ranking at the top" approach [18, 3] which maximizes the number of positives ranking above any negative data points, and they show similar performance in empirical studies [26] . In the PU learning setting, the pairwise ordering information is not complete, therefore directly applying pairwise ranking approaches may lead to biased models.
Detecting Interaction of Data Points
Atias and Sharan [4] combined prediction scores from Canonical Correlation Analysis (CCA) and label propagation model to predict associations between drugs and their side e↵ects, which is not able to use multi-domain information. There has been an increasing amount of works on recovering gene-disease associations using networkbased algorithms [34, 17, 27] which however require new data points to be included in the network and thus are limited for prediction purpose.
Gonen and Kaski [10] proposed Kernelized Bayesian Matrix Factorization (KBMF) to predict drug-target interactions by making use of the information from multiple domains via kernel methods. The Multiple Similarities Collaborative Matrix Factorization (MSCMF) [36] , was proposed for drug-target interaction prediction which approximates the indicator matrix by the product of projection matrices of drug and target similarity matrices. To enable out-of-matrix predictions, the matrix factorization type methods rely on kernel/similarity matrices which may be noisy and of poor quality. Moreover, all matrix factorization type methods are not suitable for the PU learning setting since they treat the unlabeled data points as negatives which su↵ers from the same problem as binary classification.
Natarajan and Dhillon [22] applied an inductive matrix completion method [15] to predict gene-disease associations with a bilinear model incorporating features from both domains. Theoretical analysis of inductive matrix completion for PU learning has been recently provided by [13] . However, inductive matrix completion for predicting positive interactions essentially equals to matrix factorization approaches which may confront the same problems of mistakenly categorizing unobserved positive data interactions as "negatives".
Method
Notations: In DyPU there are two data domains, (e.g., drug and disease for drug repositioning, drug and drug for DDI prediction). Assume there are N 1 data points from the first domain and N 2 data points from the second domain.
T 2 R N2⇥d2 be the data matrices of the two domains respectively. Y 2 R N1⇥N2 represents the indicator matrix where Y i,j is 1 if there is an interaction between data points x i and z j , and 0 if the interaction between them is not observed. We denote the index set of positive interactions as
+ denotes the rectifier/thresholding function where [x] + = x if u > 0, and 0 if u  0. I(·) denotes the indicator function where I(x) = 1 if x > 0, and 0 if x  0.
Scoring Functions
In this paper, we consider the pairwise interaction detection where the two data points in each pair may come from the same feature domain or totally di↵erent feature domains. In general, we define the real-valued scoring function f :
is an arbitrary monotonic non-decreasing function. When g(·) is the identity function, i.e., + etc. When the data pairs come from the same feature domain, we require the coe cient matrix W to be symmetric, i.e., W = W T , as a non-symmetric W in (3.1) will lead to inconsistent predictions, i.e.,
Compared with other approaches such as similaritybased methods, the modelling of a scoring function enables the "cold-start" type prediction, which means the prediction is not dependent on any existing training data. Moreover, compared with factorization type approaches, the bilinear model is also able to produce interpretable results. To see this, we can rewrite the scoring function as
which is essentially a function of the linear combination of feature interactions x i z j . In other words, the scores assigned to data pairs are determined by their feature interactions. For example, if the coe cient matrix W is sparse, i.e., only a small number of W i,j 's are non-zero, then one may identify relevant feature interactions for detecting data interactions.
Proposed Framework for Positive Interaction Detection
Since an unknown amount of positives are mixed together with negatives in PU learning, instead of forcing each positive to scores at the absolute top as commonly done in classification/ranking at the top problem studied in [18, 5, 25, 3] , we propose a novel loss that maximizes the number of positives ranking higher than the average score of unlabeled samples.
Then, our proposed optimization problem is:
A which aims to minimize the fraction of positive interactions ranked below the average score of unobserved interactions. Note that the proposed problem (3.3) is completely di↵erent from existing methodologies for data interaction detection since it does not impose any assumption on the data distribution of unobserved interactions. The objective function in (3.3) is discontinuous and non-convex, which makes the optimization problem di cult to solve. Therefore, we propose to minimize the following convex problem by replacing the indicator function with its convex surrogate:
where`(·) is a convex loss function that is nondecreasing and di↵erentiable. Candidates of such loss functions include the truncated quadratic loss functioǹ (x) = [1+x] 2 + , the exponential function`(x) = exp(x), the logistic loss function`(x) = log(1 + exp(x)) and so on. To prevent overfitting, we solve the following regularized problem instead of directly minimizing (3.4):
where R(W ) is a regularizer imposed on W . Typically, we assume R(W ) is convex (not necessarily smooth). Common choices of R(·) include the squared Frobenius norm k · k 2 F which is equal to the summation of square of entries in the matrix W , the trace norm k · k ⇤ which is defined as the summation of singular values of the matrix W , and the matrix l 1 norm which is the summation of the absolute value of matrix entries etc. Imposing trace norm as the regularizer leads to a low-rank solution where only a small number of underlying latent factors are assumed to contribute to the model. The squared Frobenius norm enforces the solution values to be small. The matrix l 1 norm penalty results in a sparse and interpretable solution suitable for high dimensional data.
General Optimization Methods
In general, the proposed framework DyPU considers the case when the problem is for detecting interactions between data points coming from two di↵erent feature domains. The convexity of the objective is dependent on the choice of the scoring function. If the scoring function is chosen as a bilinear function, i.e., f (x, z) = x T W z, then the objective (3.5) is convex, which consists of a convex smooth loss function and a convex regularizer (may or may not be smooth). If the regularizer is one of trace norm, Frobenius norm and the matrix l 1 norm, problem (3.5) can be e ciently solved by well-known optimization methods such as accelerate gradient descent (ACG) [24, 23] and Alternating Direction Method of Multipliers (ADMM) [6] . In particular, when the trace norm is used for regularization, one may assume that the coefficient matrix W can be factorized into the product of two low-rank matrices U 2 R d1⇥r and V 2 R d2⇥r where
2 ), i.e., W = UV T . Moreover, the trace norm of W can be equivalently defined as [9, 29] kW k⇤ = min
Thus we can solve the problem by alternately minimizing U with V fixed, and minimizing V with U fixed. When the sample interaction detection is considered within only one feature domain, a symmetric prediction is required as discussed in subsection 3.1. The optimization problem with the symmetric constraint W = W T can be solved via ADMM [6] . For regularizers such as trace norm, l 1 norm, one can adopt the proximal splitting methods [28] to e ciently solve the non-convex problem, which is guaranteed to achieve convergence.
Dual Formulation with the Rectifier Scoring Function When the rectifier function [·]
+ is chosen as the scoring function, the empirical loss in (3.4) would become
Note that in (3.6), the rectifier function also truncates the scores of positive data pairs, which leads to a smaller loss when the bilinear score function makes a negative score for a positive data pair and thus essentially weakens the requirement of "positive ranking at the top" and results in a solution of poor quality. To resolve this issue, we remove the max operator in [·] + for positive data pairs in the objective and thus obtain the following empirical loss:
When the squared Frobenius norm is used as the regularizer, we have
The loss part in objective (3.8) is convex because it is the composite of two convex functions. However, the empirical loss function is non-smooth and thus di cult to solve. To overcome the di culty brought by the rectifier function, we derive the dual form of (3.8) when the quadratic truncated function [·] 2 + is chosen for loss function, which is stated in the following theorem. 
where ↵ (i,j) 's and ⌘ (k,l) 's are dual variables associated with positive data pairs (i, j) 2 P and unlabelled sample pairs (k, l) 2 U respectively;`⇤(·) is the conjugate function of`(·) defined as follows:
where elements of ↵ and ⌘ correspond to ↵ (i,j) 's and ⌘ (k,l) 's, respectively. Let ↵ ⇤ and ⌘ ⇤ be the optimal solution to the dual problem (3.9). Then, the optimal solution W ⇤ to the primal problem (3.8) is given by
We provide the proof in the appendix 1 . We observe that the objective function of the dual problem (3.9) is smooth. Thus (3.9) can be e ciently solved by proximal (projected) gradient methods [23, 24] which were demonstrated to be very e cient for solving regularized (constrained) optimization problems. A critical step for proximal (projected) gradient methods is to compute the proximal operator (projection) problem associated with the constraints.
E cient Algorithm for Computing the Proximal Operator
We propose to use proximal algorithms to solve problem (3.9) which computes a sequence of proximal operators. To simplify the notations and we rewrite the proximal operator problem associated with problem (3.9) at the k-th step as
where n represents N U , m represents N P , dual variables ⌘ 2 R n and ↵ 2 R m , and
t (k) is the stepsize. The proximal operator problem (3.11) is highly non-trivial because of the a ne constraints on dual variables. For problem (3.11), we have the following property:
The detailed proof is provided in the appendix 2 . Based on the above theorem, we can transform the proximal operator problem in (3.11) to the following optimization problem:
where constant items are omitted. The constraint in the above optimization problem can be rewritten as
which immediately indicates that q(, s) is a piecewise quadratic function with respect to  and the points where it changes from one quadratic function to another one are included in the following set: 
Therefore, the global solution of q(, s) is
Thus, the optimal solution to (3.11) can be written as
where
One may adopt the accelerate gradient descent (ACG) algorithm [24, 23] to solve the optimization problem, which enjoys a convergence rate of O(1/k 2 ). The computation of solving problem (3.14) takes O(NP + NU ) and thus the time complexity of computing the proximal operator (3.11) is dominated by the sorting step which is O((NP + NU ) log(NP + NU )).
Experiments 4.1 Data Description
In the study, we collect 1255 drug molecules from DrugBank [33] and we use chemical structure information as the data features in the experiments. We use a fingerprint corresponding to the 881 chemical substructures to encode the drug chemical structure. Each drug is represented by an 881-dimensional binary profile whose elements encode for the presence or absence of each PubChem substructure by 1 or 0, respectively. A description of the 881 chemical substructures can be found at the website of PubChem [1] .
We collect known uses of drugs from MEDI database [32] , which is an ensemble medication indication resource based on multiple commonly used medication resources (e.g., RxNorm, MedlinePlus, and Wikipedia). Indications in MEDI are coded as International Classification of Diseases, 9th edition (ICD9) codes. We group ICD9 codes based on their first 3 digits to avoid trivial predictions (i.e., repurpose a drug from a disease to very similar diseases). Also, we exclude ill-defined ICD9 groups and rare diseases, and obtain 300 ICD9 groups as diseases in our drug repositioning study. Between our 1255 drugs and 300 diseases, there are 12,493 distinct drug-disease interactions in the dataset. We also construct a disease association matrix based on a realworld Electronic Medical Records (EMR) data warehouse, which includes a longitudinal EMR of 223,091 patients over 4 years. We use the possibility for co-occurrence of two given diseases within a 30-day window in the same individual as the association score between two diseases, and obtain a 300 by 300 matrix to denote disease associations.
We obtain DDIs from DrugBank [33] , which are extracted from drug's package inserts, as our known set of DDIs. Among our 922 drugs, there are 9,253 distinct pairwise DDIs in the dataset.
Experiment Settings and Performance Evaluation In our experiments, we compare our proposed
DyPU with rectifier scoring function (DyPU) and other four state-of-the-art approaches including inductive matrix completion (IMC) with logistic loss [22, 13] , Kernelized Bayesian Matrix Factorization factorization (KBMF) [10] , and the two-step PU learning using Naive Bayes Classifiers for both the identification of reliable negatives and classification [20] . We also include the support vector machine (SVM) as the baseline approach to investigate the performances of classical binary classification. In SVM, we use the stack of the features of each data point in a data pair as the input feature vector. The implementation of KBMF 3 is released by the authors and we use liblinear to implement SVM 4 . The IMC approach is able to use the information from both drugs and diseases and they both make low-rank assumptions. The squared Frobenius norm is used as the regularizer for the proposed DyPU approaches. In our empirical studies, the prediction performance of low-rank approaches is insensitive to the number of ranks and achieves the highest in the range between 5 and 15, thus we only report the results when the rank of coe cient matrix is set as 10.
Since the negatives are completely unknown for PU learning problems, using measurements such as AUC will lead to misleading results which essentially assume unknown labels as negatives and is, however, adopted in most existing literatures. Also, for the detection of positive interactions between data points, it is desired that positives always enjoy higher ranking scores than negatives and a good model is always able to recover more true positives than others. Therefore, besides the F1 score which is a standard evaluation metric used in PU learning, we also use the measurements from learning to rank to evaluate the performances. Specifically, we adopt the mean precision at top k (mPrec@k), the mean recall at top k (mRecall@k), the mean average precision at top k (mAP@k) and the mean F1 at top k (mF1@k). In real-world drug discovery, only a small number of confident predictions are of interest due to the limitation of resources for clinical validation. Thus, we set the number k as 1 and 3. The reported performances are obtained from 5 rounds of experiments on di↵erent splits of data pairs where 50% data pairs are used for training and the rest are used for testing.
A competent model for detecting positive interactions of data points is supposed to be robust to the ratio of observed positive interactions. Also, in practice, it is typically di cult to observe a validated positive sample interactions. Both drug repositioning and DDI prediction tasks need huge clinical e↵orts to validate. Therefore, a model that is able to make accurate predictions and insensitive to the number of observed positive data pairs is highly desired. Thus, to test the robustness of the proposed model, we randomly conceal a% of the positive data pairs in the training data by treating them as unobserved. Then we train all the models on the data with a% of positive data pairs as unlabeled and compare their performances on the testing data. Note that we only flip the labels of positive pairs in the whole training data and keep the testing data the same as before. Therefore, by decreasing the number of observed positive data pairs in training data, we evaluate the robustness of models in terms of recovering true positive interactions of data points in the model. In the experiment, the ratio of positive pairs to be concealed, a%, varies from {0%, 30%, 60%, 90%} where 0% corresponds to the original training data.
Drug Repositioning
In drug repositioning problems, an interaction between a drug and a disease exists if the drug can be used to treat the disease. We compare our proposed methods with competing approaches on detecting such drug-disease interactions. In the experiments, we extract the top 60 principal components from the disease association matrix (described in section 4.1) as the latent feature of disease. Since the traditional task of drug repositioning focuses on discovering potential e↵ective drugs for each known disease, we fix all the diseases and conduct validation procedures by randomly splitting drugs. The prediction performance achieved by di↵erent methods with di↵erent ratios of flipped positive pairs is shown in Figure 1 .
From the figure, we observe that the proposed DyPU and IMC approaches outperform baseline methods including the Two-Step Naive Bayes and SVM significantly indicating the importance of taking advantage of the information of feature interactions. For the original data set or the data set with a small number of concealed positive data pairs, our proposed method achieves comparable prediction performance with IMC. However, as the number of positive pairs decreases and useful information becomes scarcer, the prediction performances of all models decreases in di↵erent extents, which is expected. Among all the models, the proposed DyPU with the rectifier function is the most stable model which is not sensitive to the ratio of positive data pairs. The fast decay of performance obtained by the baseline methods validates the hypothesis that mistakenly categorizing unlabeled data pairs as negatives will yield biased models. We also observe that, the traditional two-step PU learning with Naive Bayes Classier achieves a fairly stable performance when the conceal-ratio is 90%, which also indicates the importance of di↵erentiating the settings of PU learning and binary classification. Besides testing the methods for traditional drug repositioning problem, we are also interested in the ability of predicting the interaction between a new drug and a new disease, which is a much harder problem. In this experiment, we split the data in both drug-wise and disease-wise manner. We train models on the pairs between training drug data points and training disease data points and test the model on the pairs where neither the drug or the disease is seen in the training stage. The validation setting mimics a real-world setting: once rare/unknown diseases without any treatment information arise, a competent drug repositioning method should predict potential new treatments based on characteristics of the new drug molecules and comorbidities of the new diseases. The prediction performance achieved by di↵erent methods with di↵erent ratios of concealed positive pairs is shown in Figure 2 .
The performance patterns are very similar to the scenario where the testing diseases are known in the training stage. We observe that the robustness of the proposed DyPU is more remarkable in this setting. For example, even when only 10% of positive interactions are used, the proposed DyPU can still achieve a comparable mean average precision@3 of using 70% of positive data pairs for training while the performance of IMC decays faster than before. Note that, in such case, traditional two-step PU learning method is not applicable.
Drug-Drug Interaction
In this experiment, we use the chemical structure features to predict the positive DDIs. The problem of DDI prediction is restricted to only one domain (i.e., members of a data pair are drugs), therefore traditional approaches are not directly applicable in this scenario. We implement our proposed DyPU with the rectifier scoring function and compare it with the IMC methods [22, 15] . To achieve symmetric predictions, the coe cient matrix W in the models of IMC is factorized into a product of a low-rank matrix U and its transpose U T , i.e., W = UU T , and we solve the formulations with proximal splitting methods.
We are interested in the general predictive power of predicting the interactions between arbitrary drug pairs which could be those of a newly developed drug (i.e., without any known DDI) and existing drugs. We design an experiment to compare the prediction abilities of our proposed framework with the IMC approach, KBMF and SVM. We randomly split the drugs into equally sized training and testing sets and train models based on the data pairs among half of the drugs, and then test their performance of predicting the positive interactions on the remaining half of the data. Similarly, for each drug in the testing set, we compute the average precision@k, precision@k, recall@k and F1@k and obtain the mean values by averaging the scores over all test- ing drugs. The predictive performance is shown in Figure 3 , which shows the advantages of our proposed DyPU in DDI prediction. Overall, it outperforms other baseline methods when an increasing number of positive data pairs are concealed, which further demonstrates the superiority of the DyPU in the PU learning setting. The IMC approach exhibits unstable prediction performance for di↵erent ratios of concealed positive data pairs, which further demonstrates that treating unlabeled data pairs as negatives will result in biased models. The DyPU with the rectifier function has an overall higher predictive power in terms of detecting positive interactions between drugs, which has the potential to alert the public to possible dangerous DDIs even before a drug o cially enters the market.
Conclusions
In this paper, we propose a novel framework named Dyadic Positive-Unlabeled learning which enables the use of the feature information of both data points in a data pair to rank positive interactions at the top. Di↵erent from most existing methodologies that treat unlabeled interactions as negatives, the proposed framework is able to detect more positive interactions by forcing the scores of positives to rank above the average score of unlabeled samples. Moreover, we derive the dual formulation of the proposed framework with the rectifier scoring function and show that the associated proximal operator admits a closed form solution. We conduct extensive experiments on real data and the experimental results show that our proposed framework achieves superior predictive performance compared with the state-of-the-art methods. Our method could help identify drug repositioning opportunities and predict potentially hazardous drug interactions, which will benefit patients by o↵ering more e↵ective and safer treatments. In future work, we plan to apply the proposed algorithms to other real-world applications with a similar problem setting.
